Prima Biomed Ltd
ASX:PRR ISIN:AU000000PRR9
Prima Biomed (ASX:PRR) is a biotechnology company based in Sydney, Australia. The Company is focused on technologies in the fields of immunology and cancer immunotherapy. Prima is focused on developing a dendritic-cell based immunotherapy targeting mucin-1 tumour expressed antigen. Prima's lead product, CVac(tm) has completed Phase IIa clinical development in Ovarian Cancer and is working to a path of US FDA IND approval.
查看其它语言版本
新闻
2011年2月21日澳洲股市报告包括：Prima BioMed Limited (ASX:PRR)将开始可能成为世界首个卵巢癌免疫疫苗的第三阶段临床试验；Redstone Resources Limited (ASX:RDS)公布西澳Tollu铜项目的更多高品位铜矿结果；Western Desert Resources Limited (ASX:WDR)报告北领地Roper Bar铁矿石项目的更多高品位铁矿石结果；Canyon Resources Limited (ASX:CAY)在布基纳法索的加快钻探作业进展更新。
###
139,610 公司背景浏览
- 本页浏览人次: (过去7日: 18) (过去30日: 50) (自发布以来: 11807)
